公开(公告)号：US20240276871A1

公开(公告)日：2024-08-15

申请号：US18604113

申请日：2024-03-13

申请人： DONGJIN SEMICHEM CO., LTD. ,  SAMSUNG DISPLAY CO., LTD.

发明人： Ho Wan HAM ,  Hyun Cheol AN ,  Byung Cheol MIN ,  Dong Jun KIM ,  Jeong Woo HAN ,  Hyung Jin LEE ,  Ja Eun ANN ,  Dong Yuel KWON ,  Dae Woong LEE ,  Hyeon Jeong IM ,  Yeong Rong PARK ,  Il Soo OH ,  Bo Ra LEE ,  Ill Hun CHO

IPC分类号： H10K85/60 ,  C07C233/58 ,  C07C255/46 ,  C07C323/22 ,  C07D295/215 ,  C07F7/08 ,  C09K11/06 ,  H10K50/858 ,  H10K85/40

CPC分类号： H10K85/615 ,  C07C233/58 ,  C07C255/46 ,  C07C323/22 ,  C07D295/215 ,  C07F7/081 ,  C09K11/06 ,  H10K50/858 ,  H10K85/40 ,  H10K85/626 ,  H10K85/656 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2603/74 ,  C09K2211/1011

摘要： A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

公开(公告)号：US20240000732A1

公开(公告)日：2024-01-04

申请号：US17854360

申请日：2022-06-30

申请人： JOONG HO MOON ,  MICHELLE MIRANDA

发明人： JOONG HO MOON ,  MICHELLE MIRANDA

IPC分类号： A61K31/17 ,  C07D295/215 ,  C07C279/12 ,  A61K31/496 ,  A61K31/498 ,  A61K31/47 ,  A61K31/277 ,  A61K31/5377 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/133 ,  A61P31/06 ,  C08G65/00 ,  C08G71/02

CPC分类号： A61K31/17 ,  C07D295/215 ,  C07C279/12 ,  A61K31/496 ,  A61K31/498 ,  A61K31/47 ,  A61K31/277 ,  A61K31/5377 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/133 ,  A61P31/06 ,  C08G65/00 ,  C08G71/02 ,  C07C2601/16

摘要： The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.

公开(公告)号：US11773055B2

公开(公告)日：2023-10-03

申请号：US17673381

申请日：2022-02-16

申请人： Chorda Pharma, Inc.

发明人： Richard Daniel Carliss ,  Jianxing William Huang

IPC分类号： C07C271/40 ,  C07C271/06 ,  C07D295/215 ,  C07D295/205

CPC分类号： C07C271/40 ,  C07C271/06 ,  C07D295/205 ,  C07D295/215

摘要： Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.

公开(公告)号：US09969743B2

公开(公告)日：2018-05-15

申请号：US15463051

申请日：2017-03-20

申请人： Southern Research Institute

发明人： Subramaniam Ananthan

IPC分类号： C07D487/04 ,  C07D295/15 ,  C07D239/42 ,  C07D215/46 ,  C07D213/14 ,  C07D403/12 ,  C07D401/12 ,  C07D401/14 ,  C07D215/38 ,  C07D295/215 ,  C07D471/04

CPC分类号： C07D487/04 ,  C07D211/60 ,  C07D213/14 ,  C07D215/06 ,  C07D215/38 ,  C07D215/46 ,  C07D239/26 ,  C07D239/30 ,  C07D239/42 ,  C07D239/74 ,  C07D295/033 ,  C07D295/13 ,  C07D295/215 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

摘要： Provided are compounds represented by the formula: In which: Y is an unbranched, saturated or unsaturated hydrocarbon chain with 2-5 hydrocarbon atoms R1=aryl R2=NR3R4 wherein R3 and R4 together form a heterocycle or R2=4-substitutedcyclohexyl, 1-substitutedpiperidine-4-yl or imidazo(1,2-a)azine-2-yl when Y is as defined above and R1 is a heterocycle other than benzothiophene pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition that is capable of treatment with a partial agonist or antagonist of the dopamine D2/D3 receptors. The compounds are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as Parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders. Also provided are processes for the preparation of compounds of the present disclosure.

公开(公告)号：US09862693B2

公开(公告)日：2018-01-09

申请号：US14566055

申请日：2014-12-10

申请人： The Regents of the University of California

发明人： Richard J. Pietras ,  Michael E. Jung ,  Diana C. Marquez-Garban ,  Gang Deng

IPC分类号： C07D295/215 ,  C07D203/20 ,  C07D211/16 ,  C07D213/78 ,  C07D239/28 ,  C07D401/12 ,  A61K31/155 ,  C07C279/26 ,  A61K31/4025 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  C07C279/22

CPC分类号： C07D295/215 ,  A61K31/155 ,  A61K31/4025 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  C07C279/22 ,  C07C279/26 ,  C07D203/20 ,  C07D211/16 ,  C07D213/78 ,  C07D239/28 ,  C07D401/12

摘要： Presented herein inter alia are novel compounds and methods of using the same for the treatment of cancers.

公开(公告)号：US09822206B2

公开(公告)日：2017-11-21

申请号：US13822976

申请日：2010-09-14

申请人： My T. Nguyen ,  Akha Phan ,  Viet-Thu Nguyen-Truong ,  Marc-André Locas

发明人： My T. Nguyen ,  Akha Phan ,  Viet-Thu Nguyen-Truong ,  Marc-André Locas

IPC分类号： C08F220/36 ,  C08F220/60 ,  C08F226/06 ,  C08F212/10 ,  C08F220/50 ,  B41C1/10 ,  C07C233/84 ,  C07C255/19 ,  C07C275/34 ,  C07C275/42 ,  C07C311/46 ,  C07D207/40 ,  C07D209/86 ,  C07D233/74 ,  C07D295/215 ,  C08F12/22 ,  C08F12/24 ,  C08F12/26 ,  C08F12/30 ,  C08F212/14 ,  C08F220/06 ,  C08F220/14 ,  C09D125/18 ,  G03F7/004 ,  C08F2/46 ,  C08F220/38 ,  C08F220/34

CPC分类号： C08F226/06 ,  B41C1/1008 ,  B41C2210/02 ,  B41C2210/08 ,  B41C2210/22 ,  B41C2210/24 ,  C07C233/54 ,  C07C233/84 ,  C07C255/19 ,  C07C275/34 ,  C07C275/42 ,  C07C311/46 ,  C07D207/40 ,  C07D209/86 ,  C07D233/74 ,  C07D295/215 ,  C08F2/46 ,  C08F12/22 ,  C08F12/24 ,  C08F12/26 ,  C08F12/30 ,  C08F212/10 ,  C08F212/14 ,  C08F220/06 ,  C08F220/14 ,  C08F220/36 ,  C08F220/50 ,  C08F2220/343 ,  C08F2220/346 ,  C08F2220/387 ,  C08F2220/603 ,  C08F2220/606 ,  C09D125/18 ,  G03F7/004 ,  C08F2220/1808 ,  C08F220/18

摘要： There is provided a copolymer having the general structure below, wherein a, b, and d are molar ratios varying between about 0.01 and about 0.90 and c is a molar ratio varying between about 0.01 and about 0.90; A1 represents monomer units comprising a cyano-containing pendant group in which the cyano is not directly attached to the backbone of the copolymer; A2 represents monomer units comprising two or more hydrogen bonding sites; A3 represents monomer units that increase solubility in organic solvents; and A4 represents monomer units that increase solubility in aqueous alkaline solutions. There is also provided a near-infrared radiation-sensitive coating composition comprising this copolymer as well as a positive-working thermal lithographic printing plate comprising a near-infrared radiation-sensitive coating comprising this copolymer, a method of producing such a printing plate, and finally a method of printing using such a printing plate. Formula (I).

公开(公告)号：US09802908B2

公开(公告)日：2017-10-31

申请号：US14969920

申请日：2015-12-15

申请人： Thomas P. Daly

发明人： Thomas P. Daly

IPC分类号： C07C235/00 ,  C07D295/215 ,  C07C233/36

CPC分类号： C07D295/215 ,  C07C233/36

摘要： Ethyl benzyl quaternaries having superior anti-fungal properties versus their benzyl quaternary analogs. The ethylbenzyl amidoamine quaternaries of the present invention are easily produced without significant waste and with minimal capital, while possessing improved antimicrobial properties.

公开(公告)号：US20170204076A1

公开(公告)日：2017-07-20

申请号：US15324619

申请日：2015-07-06

申请人： INCELLA GMBH ,  KARLSRUHER INSTITUT FÜR TECHNOLOGIE

发明人： Linxian Li ,  Girish Karadka Shankara ,  Xing Du ,  Yihang Wu ,  Gary Davidson ,  Pavel Levkin

IPC分类号： C07D295/215 ,  C07D295/13 ,  C07C323/44 ,  C07C317/18 ,  C07C315/04 ,  C07C317/28 ,  A61K9/127 ,  C12N15/113 ,  A61K31/7088 ,  C07C319/12 ,  C07C323/12 ,  C07C323/25

CPC分类号： C07D295/215 ,  A61K9/1272 ,  A61K31/7088 ,  C07C315/04 ,  C07C317/18 ,  C07C317/28 ,  C07C319/12 ,  C07C323/12 ,  C07C323/25 ,  C07C323/44 ,  C07C323/65 ,  C07D295/04 ,  C07D295/13 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/32

摘要： The present invention provides novel amino lipids and a method for synthesizing these compounds. According to the invention, the amino lipids have a structure of the following formula: wherein Z is hydrogen or —X1R1, R1 and R2 are the same or different and independently C6-C24 alkyl, C6-C24 alkenyl, C6-C24 alkynyl, or C6-C24 acyl, X1 and X2 are the same or different, S, S═O or S(═O)2, Y is or heterocycles of the formula wherein k and l are integers from 0 to 2, R3 and R4 are either the same or different and independently C1-C12 alkyl, C1-C12 alkenyl, or C1-C12 alkynyl, wherein alkyl, alkenyl or alkynyl may be optionally substituted with a C1-C6 hydrocarbyl group, or R3 and R4 optionally join to form, together with the nitrogen atom to which they are bound, an optionally substituted N-heterocyclic ring of 3 to 10 atoms comprising 1 to 7 nitrogen atoms, or R3 and R4 are the same or different alkyl amines; R5 and R6 are absent or are hydrogen or C1-C12 alkyl, R7 is hydrogen or C1-C12 alkyl, m is an integer from 1 to 12, n is an integer from 1 to 12, and p is an integer from 1 to 3, wherein Y═N for p=2 or 3.

公开(公告)号：US20170152230A9

公开(公告)日：2017-06-01

申请号：US14785812

申请日：2014-04-29

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Changsik LEE ,  Hyun-Mo YANG ,  Hojin CHOI ,  Dohoon KIM ,  Soyoung KIM ,  Nina HA ,  Hyojin LIM ,  Eunhee KO ,  Seongae YOON ,  Daekwon BAE

IPC分类号： C07D231/56 ,  C07D209/14 ,  C07D213/40 ,  C07D401/12 ,  C07D403/12 ,  C07D239/26 ,  C07D215/12 ,  C07D213/75 ,  C07D295/215 ,  C07D239/42

CPC分类号： C07D231/56 ,  C07D207/08 ,  C07D207/10 ,  C07D209/08 ,  C07D209/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/52 ,  C07D213/40 ,  C07D213/74 ,  C07D213/75 ,  C07D215/12 ,  C07D239/26 ,  C07D239/42 ,  C07D265/30 ,  C07D295/215 ,  C07D309/08 ,  C07D309/10 ,  C07D317/58 ,  C07D319/18 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.

公开(公告)号：US09586928B2

公开(公告)日：2017-03-07

申请号：US14118116

申请日：2012-05-16

申请人： Theodore Mark Kamenecka ,  Patrick R. Griffin ,  Youseung Shin ,  Yuanjun He ,  Anne-Laure Blayo ,  Brent R. Lyda ,  Marcel Koenig ,  Naresh Kumar ,  Thomas Burris

发明人： Theodore Mark Kamenecka ,  Patrick R. Griffin ,  Youseung Shin ,  Yuanjun He ,  Anne-Laure Blayo ,  Brent R. Lyda ,  Marcel Koenig ,  Naresh Kumar ,  Thomas Burris

IPC分类号： C07D213/74 ,  C07D213/36 ,  C07D295/096 ,  C07D295/185 ,  C07D295/195 ,  C07D295/26 ,  C07D277/64 ,  C07D207/09 ,  C07D211/22 ,  C07D233/61 ,  C07D317/50 ,  C07D213/82 ,  C07D215/12 ,  C07D317/58 ,  C07D319/20 ,  C07D333/20 ,  C07D333/34 ,  C07D401/12 ,  C07D277/28 ,  C07D209/14 ,  C07D295/205 ,  C07D295/215 ,  C07D213/61 ,  C07D213/64 ,  C07D307/24 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06

CPC分类号： C07D317/50 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/09 ,  C07D209/14 ,  C07D211/22 ,  C07D213/36 ,  C07D213/61 ,  C07D213/64 ,  C07D213/74 ,  C07D213/82 ,  C07D215/12 ,  C07D233/61 ,  C07D277/28 ,  C07D277/64 ,  C07D295/096 ,  C07D295/185 ,  C07D295/205 ,  C07D295/215 ,  C07D295/26 ,  C07D307/24 ,  C07D317/58 ,  C07D319/20 ,  C07D333/20 ,  C07D333/34 ,  C07D401/12

摘要： The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ, of formula with the variable atoms as defined herein and R1 comprising a hydroxyl- or alkoxyl-substituted fluoroalkyl group. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided.

摘要翻译： 本发明提供了视黄酸受体相关的孤儿受体如RORα，ROR和bgr或RORγ的小分子调节剂。 本发明的化合物可以是无效作用于LXR受体或其它核受体或其他生物靶标的有效调节剂。 还提供调节ROR的方法和治疗代谢紊乱，免疫疾病，癌症和中枢神经系统疾病的方法，其中医学指示ROR的调节。